NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
11 trialsNCT02125617 2026-01-14
uPARCRPC
Rigshospitalet, Denmark
Terminated
NCT03777982 2024-09-19
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute
Phase 3 Terminated
NCT04458311 2024-04-25
ACTIon
Institute of Cancer Research, United Kingdom
Phase 1/2 Terminated
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT01681433 2022-07-11
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03827473 2020-06-25
ACADEMIC
University of Utah
Phase 2 Terminated
NCT01994590 2019-03-19
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01845792 2018-06-04
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
University of Colorado, Denver
Phase 2 Terminated
NCT01735396 2017-05-12
Abiraterone Acetate Trial in African American Prostate Cancer Patients
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT02656615 2017-03-24
ABI-RE
Cantonal Hospital of St. Gallen
Phase 2 Terminated